MA-ELECTRA-VEHICLES
11.4.2022 08:02:11 CEST | Business Wire | Press release
On April 5, 2022, automotive industry leader Alexander (Alex) Hitzinger was appointed to the Board of Directors at Electra Vehicles, Inc. as an Independent Board Member. The appointment marks another critical milestone for the growing AI battery software startup as the company expands its expert roster of electric vehicle leaders from the transportation industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220410005015/en/
Hitzinger boasts an extensive engineering and leadership career where he led key autonomous and electric vehicle projects. His career began at Toyota as a development engineer before working in the Formula 1 world as Head of Formula 1 Development at Cosworth and Head of Advanced Technologies at Red Bull’s Formula 1 Team. His penchant for leading cutting edge automotive technology projects led him to serve as Technical Director for the three times victorious Porsche 919 at the 24 Hours of Le Mans and Head of Product Design at Apple for Project Titan before co-founding and serving as CEO at ARTEMIS, where he lead the creation of a visionary autonomous vehicle concept. Most recently, Hitzinger served as Senior Vice President of Autonomous Driving at VW Group and Member of the Executive Board VWN, where he was involved in the development of the ID Buzz. With more than 20 years of experience in the automotive and electric vehicle industries, Hitzinger begins a new phase of his career with the aim of supporting promising young companies with disruptive technologies as they enter the automotive and electric vehicle world stage.
“I am looking for outstanding companies, with industry leading technologies, where I can help the management in deriving a successful strategy for scaling the company and the technology. Electra Vehicles, Inc. is exactly this type of company,” says Hitzinger. “The electrification of transportation is in full swing, but in many areas of the technology stack, there are still outdated technologies deployed. Electra is closing one of these gaps with its sophisticated battery performance management, and therefore I couldn’t be happier about joining Electra’s Board of Directors.”
CEO and Co-founder of Electra Vehicles, Fabrizio Martini, expresses his delight at welcoming Hitzinger to the Board: “The Electra team is honored, proud, and glad to welcome on its Board of Directors an extraordinary visionary like Alex Hitzinger. Alex is a world-renowned expert and award-winning talent in the Mobility sector. His experience, knowledge, and vision will guide Electra Vehicles, Inc. to make a significant global impact. I am genuinely excited to start partnering with Alex to bring the most advanced ML/AI-based technology worldwide for battery management solutions in the marketplace to enhance today’s transition to electric transportation.”
About Electra Vehicles, Inc.
Electra Vehicles is a leading B2B AI software company headquartered in Boston, MA, USA with a presence in Italy that produces embedded and Cloud-connected software to optimize the performance of electric vehicle battery systems for range, lifetime, charging, and safety benefits. Electra’s onboard EVE-Ai™ 360 Adaptive Controls and Cloud-based EVE-Ai™ Fleet Analytics are software that provide battery system performance insights, battery-conscious driver recommendations, and intelligent charging control strategies based on a continuously updating Adaptive Cell Model, making Electra’s EVE-Ai™ a necessity for electrified applications worldwide. In 2021, Electra Vehicles, Inc. became a BlackBerry IVY Fund investee and is a proud member of the BlackBerry IVY ecosystem.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220410005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom